Westlake Village BioPartners launches new fund, appoints new and experienced directors
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Male birth control could be the next step in preventing pregnancy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Westlake Village BioPartners launches new $450M fund
Westlake Village BioPartners, a venture capital firm focused on biotechnology startups in the Conejo Valley and the rest of greater Los Angeles, announced the closing of its third fund on July 17, raising $450 million that will go toward early-stage next-generation biotechnology companies. The new fund will be managed by founding managing director Beth Seidenberg, M.D., Read More →
<strong>Central Coast healthcare industry embraces innovations in cancer treatment</strong>
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
SDRI highlights big breakthroughs in 2022
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Central Coast health providers to pay out $68M in settlement
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Additional approval bolsters Amgen cancer treatment
Correction: The headline on this article has been updated. The U.S. Food and Drug Administration has approved Amgen’s supplemental biologics license for Blincyto, which treats adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia, the Thousand Oaks-based life sciences giant announced on June 20. The patients have the leukemia in first or second Read More →
